Abstract
In this work, we computationally identified the most detrimental missense mutations of ABL tyrosine kinase in Chronic Myelogenous Leukemia (CML) and analyzed the drug resistance from these detrimental missense mutations. Out of 45 missense mutations, 20 variants were commonly found less stable, deleterious and damaging by I-Mutant2.0, SIFT and PolyPhen programs respectively. Subsequently, we performed modeling of these 20 variants to understand their change in conformations with respect to native ABL tyrosine kinase by computing their RMSD (Root Mean Square Deviation). Further, the native and 20 mutants were docked with the drug ‘imatinib’ to find out the drug resistance of these detrimental missense mutations. Among the 20 mutants, we found by docking studies that 12 mutants, namely M244V, Q252H, Y253H, K285N, T315I, F317L, F317I, S349L, M351T, E355G, S417Y and W430L had less binding affinity with imatinib than the native type. Finally, we analyzed that the loss of binding affinity of these 12 mutants were due to altered flexibility in their binding amino acids with imatinib as compared with native type by normal mode analysis. In our work, we found the novel data that majority of the drug binding amino acids in those 12 mutants had encountered the loss of flexibility which could be the theoretical basis for the cause of drug resistance.
Keywords: Missense mutation, ABL tyrosine kinase, Imatinib, Modeling, Docking, Flexibility, Chronic Myelogenous Leukemia, Adenosine triphosphate, Swissprot, Protein Data Bank, I-Mutant 2.0, SIFT, PolyPhen, DDG, Tolerance index, PSIC SD, RMSD, Force Field, Gromacs, Atomic Contact Energy, PatchDock, Normal mode analysis, B-factors, ElNemo, Ligand Contact Tool
Current Signal Transduction Therapy
Title: In Silico Identification and Analysis of Drug Resistant Mutants of ABL Tyrosine Kinase Based on Detrimental Missense Mutations
Volume: 6 Issue: 3
Author(s): R. Rajasekaran, C. George Priya Doss, G. Arun Prasad and Rao Sethumadhavan
Affiliation:
Keywords: Missense mutation, ABL tyrosine kinase, Imatinib, Modeling, Docking, Flexibility, Chronic Myelogenous Leukemia, Adenosine triphosphate, Swissprot, Protein Data Bank, I-Mutant 2.0, SIFT, PolyPhen, DDG, Tolerance index, PSIC SD, RMSD, Force Field, Gromacs, Atomic Contact Energy, PatchDock, Normal mode analysis, B-factors, ElNemo, Ligand Contact Tool
Abstract: In this work, we computationally identified the most detrimental missense mutations of ABL tyrosine kinase in Chronic Myelogenous Leukemia (CML) and analyzed the drug resistance from these detrimental missense mutations. Out of 45 missense mutations, 20 variants were commonly found less stable, deleterious and damaging by I-Mutant2.0, SIFT and PolyPhen programs respectively. Subsequently, we performed modeling of these 20 variants to understand their change in conformations with respect to native ABL tyrosine kinase by computing their RMSD (Root Mean Square Deviation). Further, the native and 20 mutants were docked with the drug ‘imatinib’ to find out the drug resistance of these detrimental missense mutations. Among the 20 mutants, we found by docking studies that 12 mutants, namely M244V, Q252H, Y253H, K285N, T315I, F317L, F317I, S349L, M351T, E355G, S417Y and W430L had less binding affinity with imatinib than the native type. Finally, we analyzed that the loss of binding affinity of these 12 mutants were due to altered flexibility in their binding amino acids with imatinib as compared with native type by normal mode analysis. In our work, we found the novel data that majority of the drug binding amino acids in those 12 mutants had encountered the loss of flexibility which could be the theoretical basis for the cause of drug resistance.
Export Options
About this article
Cite this article as:
Rajasekaran R., George Priya Doss C., Arun Prasad G. and Sethumadhavan Rao, In Silico Identification and Analysis of Drug Resistant Mutants of ABL Tyrosine Kinase Based on Detrimental Missense Mutations, Current Signal Transduction Therapy 2011; 6 (3) . https://dx.doi.org/10.2174/157436211797483903
DOI https://dx.doi.org/10.2174/157436211797483903 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Eliminating Ovarian Cancer Stem Cells: A Potential Therapeutic Target for Ovarian Cancer Chemoresistance
Current Protein & Peptide Science (1→3)-α-D-Glucans from Aspergillus spp.: Structural Characterization and Biological Study on their Carboxymethylated Derivatives
Current Drug Targets The link between Hepatic Vitamin A Metabolism and Nonalcoholic Fatty Liver Disease
Current Drug Targets Precision Mechanics with Multifunctional Tools: How HnRNP K and HnRNPs E1/E2 Contribute to Post-Transcriptional Control of Gene Expression in Hematopoiesis
Current Protein & Peptide Science Recent Advance in the Research of Flavonoids as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Retinoid Receptors in Inflammatory Responses: A Potential Target for Pharmacology
Current Drug Targets - Inflammation & Allergy Anti-Tumour Activity of Glycodendrimer Nanoparticles in a Subcutaneous MEC-1 Xenograft Model of Human Chronic Lymphocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Cytotoxic, Apoptotic and DNA Synthesis Inhibitory Effects of Some Thiazole Derivatives
Letters in Drug Design & Discovery Improving Cancer Therapeutics by Molecular Profiling
Current Drug Metabolism The Medicinal Chemistry Implications of the Anticancer Effects of Aspirin and Other NSAIDs
Mini-Reviews in Medicinal Chemistry Factors Controlling Chromatin Organization and Nucleosome Positioning for Establishment and Maintenance of HIV Latency
Current HIV Research Treatment of Chronic Myeloid Leukemia Elderly Patients in the Tyrosine Kinase Inhibitor Era
Current Cancer Drug Targets Intracellular Restriction Factors In Mammalian Cells - An Ancient Defense System Finds A Modern Foe
Current HIV Research Synthesis and Evaluation of Haloacetyl, α-Bromoacryloyl and Nitrooxyacetyl Benzo[b]furan and Benzo[b]thiophene Derivatives as Potent Antiproliferative Agents Against Leukemia L1210 and K562 Cells
Letters in Drug Design & Discovery Plant Cells as Pharmaceutical Factories
Current Pharmaceutical Design Myeloma Cells and Their Interactions With the Bone Marrow Endothelial Cells
Current Immunology Reviews (Discontinued) The Anticancer Face of Interferon Alpha (IFN-Alpha): From Biology to Clinical Results, with a Focus on Melanoma
Current Medicinal Chemistry Pharmacogenetics of Phase I and Phase II Drug Metabolism
Current Pharmaceutical Design Withdrawal Notice: The Recent Advancement in the Field of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) for Aiming Breast Cancer
Current Drug Metabolism